TNFRSF11A and prostate carcinoma: Also PTHrP and its receptor have been found in bone metastases and in primary prostate cancer, and it has been demonstrated that prostate tumour cells are able to directly express a form of RANK ligand, which directly induces bone resorption [91], revealing that osteolytic activity is present in prostate cancer [92].